Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Samjin Pharmaceutical Co., Ltd. (005500:KRX), powered by AI.
Samjin Pharmaceutical Co., Ltd. is currently trading at ₩18,350. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Samjin Pharmaceutical Co., Ltd. on Alpha Lenz.
Samjin Pharmaceutical Co., Ltd.'s P/E ratio is 10.1.
“Samjin Pharmaceutical Co., Ltd. trades at a P/E of 10.1 (undervalued) with solid ROE of 8.8%.”
Ask for details →Samjin Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, primarily engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company focuses on the production of a diverse range of medications including prescription drugs, over-the-counter (OTC) products, and health supplements. Its portfolio addresses various therapeutic areas such as cardiovascular diseases, metabolic disorders, and microbial infections. With a strong commitment to innovation, Samjin Pharmaceutical actively invests in R&D to develop new drugs and improve existing formulations, enhancing its competitiveness in the global pharmaceutical market. Samjin also plays a crucial role in ensuring drug affordability and accessibility, particularly within the South Korean healthcare system, while maintaining high standards of quality and efficacy. As a key contributor to public health, the company continues to expand its international presence through strategic partnerships and compliance with global regulatory standards.
“Samjin Pharmaceutical Co., Ltd. trades at a P/E of 10.1 (undervalued) with solid ROE of 8.8%.”
Ask for details →Samjin Pharmaceutical Co., Ltd. (ticker: 005500) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 586 employees. Market cap is $244.4B.
The current price is ₩18,350 with a P/E ratio of 10.11x and P/B of 0.84x.
ROE is 8.76% and operating margin is 8.66%. Annual revenue is $309.1B.